Your session is about to expire
← Back to Search
Rivaroxaban vs Aspirin for Multiple Myeloma (RithMM Trial)
RithMM Trial Summary
This trial will compare the effects of two different therapies, ASA vs. Rivaroxaban, in newly diagnosed or relapsed and refractory multiple myeloma patients treated with Len-Dex combination therapy.
RithMM Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowRithMM Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2020 Phase 3 trial • 179 Patients • NCT02164578RithMM Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am on blood thinners for clotting issues or to prevent stroke due to irregular heartbeat.The doctor thinks you may live for less than 3 months.I have not had uncontrolled heart problems in the last 6 months.My diabetes or kidney disease is not well-managed.I have not had a major bleeding event in the last 3 months.I am taking medication to prevent blood clots due to a heart or neck artery stent.I am currently taking lenalidomide as my only treatment.I am not willing or able to agree to join the study.I have not had major surgery in the last 2 weeks.I have been diagnosed with Multiple Myeloma.I have had a stomach or duodenal ulcer in the last 2 years.I am about to start treatment with Lenalidomide and Dexamethasone.I am 18 years old or older.I haven't had cancer, except for basal cell or squamous carcinoma, in the last 2 years.
- Group 1: Len-Dex+ASA
- Group 2: Len-Dex+Rivaroxaban
- Approved for 20 Other Conditions - This treatment demonstrated efficacy for 20 other conditions.
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Can people with the required qualifications join this trial right now?
"This trial, which was first posted on 7/30/2023 is recruiting patients right now. The last update to the posting on clinicaltrials.gov was 10/3/2022"
How many different people are included in this clinical trial?
"That is accurate. The clinicaltrials.gov website has information revealing that this trial is still recruiting patients. This particular study was originally posted on 7/30/2023 and was edited for the last time on 10/3/2022. They are looking to enroll 86 individuals from 1 location."
Would this experiment be beneficial for elderly patients outside of the age limit?
"This study is looking for individuals over the age of 18 and younger than 90."
Are there other examples in medical history of this type of experiment?
"There are 231 ongoing clinical trials testing the efficacy of Len-Dex+Rivaroxaban in 1585 cities and 64 countries. The first study began in 2002 and, after completing Phase 3 drug approval, 413 patients were involved. 710 studies have been conducted in the 18 years since the original trial."
Could I take part in this experiment if I qualify?
"Candidates for this clinical trial must be between 18 and 90 years old and have a diagnosis of multiple myeloma. At the moment, there are approximately 86 potential participants needed."
What are the common treatments that Len-Dex+Rivaroxaban help with?
"Len-Dex+Rivaroxaban can provide relief from pain, myocardial infarction, and catarrh."
Share this study with friends
Copy Link
Messenger